Third Rock Ventures Pumps $38 Million Into New Firm Focused On Genetic Heart Disease
This article was originally published in The Pink Sheet Daily
Executive Summary
Third Rock is the sole Series A investor in MyoKardia, which plans to use personalized medicine to treat hypertrophic and dilated cardiomyopathies.